U.S. markets open in 33 minutes

Mallinckrodt plc (MNKKQ)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2650+0.1525 (+135.56%)
At close: 3:59PM EST

Mallinckrodt plc

College Business & Technology Park
Cruiserath Blanchardstown
Dublin 15
Ireland
353 1 696 0000
http://www.mallinckrodt.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees3,400

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark Christopher TrudeauPres, CEO & Director4.61MN/A1961
Mr. Bryan M. ReasonsExec. VP & CFO1.73MN/A1967
Mr. Hugh M. O'NeillExec. VP & Chief Commercial and Operations Officer1.91MN/A1963
Dr. Steven J. RomanoExec. VP & Chief Scientific Officer2.12MN/A1959
Mr. Mark J. CaseyExec. VP & Chief Legal Officer2.06MN/A1963
Mr. Daniel J. Speciale CPA, CPAVP of Fin. & Investor Relations OfficerN/AN/AN/A
Ms. Michele RobertsonSr. VP & Chief Compliance OfficerN/AN/AN/A
Ms. Brandi RobinsonSr. VP & Chief Communications OfficerN/AN/AN/A
Mr. Ian J. WatkinsExec. VP & Chief HR OfficerN/AN/A1963
Mark TyndallSr. VP of Gov. Affairs & Chief Counsel of LitigationN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

Mallinckrodt plc’s ISS Governance QualityScore as of November 1, 2019 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.